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Abstract
Cherubism is a skeletal dysplasia characterized by bilateral and symmetric fibro-osseous lesions limited to the
mandible and maxilla. In most patients, cherubism is due to dominant mutations in the SH3BP2 gene on
chromosome 4p16.3. Affected children appear normal at birth. Swelling of the jaws usually appears between 2 and
7 years of age, after which, lesions proliferate and increase in size until puberty. The lesions subsequently begin to
regress, fill with bone and remodel until age 30, when they are frequently not detectable.
Fibro-osseous lesions, including those in cherubism have been classified as quiescent, non-aggressive and
aggressive on the basis of clinical behavior and radiographic findings. Quiescent cherubic lesions are usually seen
in older patients and do not demonstrate progressive growth. Non-aggressive lesions are most frequently present
in teenagers. Lesions in the aggressive form of cherubism occur in young children and are large, rapidly growing
and may cause tooth displacement, root resorption, thinning and perforation of cortical bone.
Because cherubism is usually self-limiting, operative treatment may not be necessary. Longitudinal observation and
follow-up is the initial management in most cases. Surgical intervention with curettage, contouring or resection
may be indicated for functional or aesthetic reasons. Surgical procedures are usually performed when the disease
becomes quiescent. Aggressive lesions that cause severe functional problems such as airway obstruction justify
early surgical intervention.
Disease name and definition
Cherubism (MIM ID# 118400) or multilocular cystic dis-
ease of the jaws was first recognized as a separate entity
in 1933 by William A. Jones in a family with several
affected members [1,2]. He designated the descriptive
name “cherubism” because “the full round cheeks and
the upward cast of the eyes give the children a peculiarly”
cherubic appearance [2,3]. Because this name so accu-
rately captured the clinical features of the disease, it
became the standard nomenclature.
Cherubism is defined by the appearance of symmetri-
cal, multilocular, expansile radiolucent lesions of the
mandible and/or the maxilla that typically first appear at
the age of 2 to 7 years. Swelling of submandibular lymph
nodes in the early stages contributes to the fullness of the
face. As the soft fibrous dysplastic tissue in the lesions
expands the protuberant masses can infiltrate the orbital
floor and cause the characteristic upward tilting of the
eyes, exposing the sclera below the iris. Cherubism
lesions are limited to the jaws and in most cases the dys-
plastic expansile masses begin to regress with the onset
of puberty.
Grading systems for cherubism have been suggested to
describe location and severity of lesions. The first sys-
tem distinguished Grade 1: fibro-osseous bilateral and
symmetrical expansions in the rami of the mandible;
G r a d e2 :m o r es e v e r ei n v o l v e m e n to ft h er a m u sa n d
body of the mandible and the tuberosity region of the
maxillae; and Grade 3: involvement of maxilla and
mandible in their entirety with considerable facial defor-
mity [4,5]. Raposo-Amaral simplified the grading system
of Motamedi [6] and added a 6
th Grade to describe the
involvement of the orbits [7] (Table 1). While some
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extent of lesions, other authors do not use any grading
system because the expression of cherubism in each
patient is unique. Important for the clinician is the bio-
logic/clinical behavior of the lesions in each patient: rate
of growth, size, cortical bone perforation or thinning,
tooth displacement and the functional deficits.
Epidemiology
Cherubism is a very rare disorder with only an estimated
300 cases reported in the literature. Because of its rarity,
it is difficult to determine a disease frequency for this dis-
order. Cherubism affects males and females with equal
frequency and has been reported in patients of all racial
and ethnic backgrounds. Unequal penetrance between
males and females should be considered a historical arti-
fact, which is based on misinterpretation of a thorough
clinical investigation [8,9]. The delayed disease onset and
misdiagnosis of adult patients with a mild form of cher-
ubism may have contributed to this misconception.
Clinical description
The hallmark of cherubism is the development of sym-
metrical multilocular radiolucent expansile lesions in the
mandible and/or the maxilla, which typically first appear
at the age of 2 to 7 years. Submandibular and cervical
lymph nodes are enlarged during the early stages of cher-
ubism. Severity of the disease phenotype is highly vari-
able, even within a family. Patients with a mild form of
cherubism may develop only small symmetric lesions in
the mandible. The first radiographic signs of cherubism
are usually found in the region of the mandibular angle.
These radiolucent lesions are asymptomatic but may
affect development or eruption of permanent molars.
The more progressive form of cherubism manifests with
multiple symmetrical lesions in the mandible or involves
the mandible and maxilla with singular or multiple
lesions (see also Table 1).
Although, cherubism lesions are usually limited to the
mandible and the maxilla, there are rare reports of invol-
vement of the zygomatic arches and condyles [6,10].
Lesions in patients with the progressive form of cherub-
ism result in extensive bone resorption and leave only a
fenestrated shell of cortical bone. Fibrous tissue masses
can expand the cortical bone and lead to facial swelling.
When expansile fibrous tissue masses invade the floor
and walls of the orbits they can cause upward tilting or
displacement of the globes.
Most cases of cherubism regress spontaneously after
puberty. There are rare instances when lesions in sus-
pected cherubism patients are persist or actively grow in
young adults [11,12].
Table 1 Cherubism grading system according to Motamedi (1998) and Raposo-Amaral (2007)
Grade I
Lesions of the mandible without signs of root resorption
Class 1 solitary lesion of the mandibular body
Class 2 multiple lesions of the mandibular body
Class 3 solitary lesion of the ramus
Class 4 multiple lesions of the rami
Class 5 lesions involving the mandibular body and rami
Grade II
Lesions involving the mandible and maxilla without signs of root resorption
Class 1 lesions involving the mandible and maxillary tuberosities
Class 2 lesions Involving the mandible and anterior maxilla
Class 3 lesions involving the mandible and entire maxilla
Grade III
Aggressive lesions of the mandible with signs of root resorption
Class 1 solitary lesion of the mandibular body
Class 2 multiple lesions of the mandibular body
Class 3 solitary lesion of the ramus
Class 4 multiple lesions of the mandibular rami
Class 5 lesions involving the mandibular body and rami
Grade IV
Lesions involving the mandible and maxilla and showing signs of root resorption
Class 1 lesions involving the mandible and maxillary tuberosity
Class 2 Lesions involving the mandible and anterior maxilla
Class 3 lesions involving the mandible and entire maxilla
Grade V
The rare, massively growing, aggressive, and extensively deforming juvenile cases
involving the maxilla and mandible, and may include the coronoid and condyles
Grade VI
The rare, massively growing, aggressive, and extensively deforming juvenile
lesions involving the maxilla, mandible and orbits
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As noted above, cherubism is typically limited to the cra-
niofacial region. However, there are three reports in the
literature that refer to involvement of the ribs. A 17-year-
old girl from a family with 3 affected cherubism patients
showed symptomless non-expansile lesions at the anterior
ends of her ribs [13]. An 8-year-old boy presented with
typical bilateral facial swelling and radiographic evidence
of cherubism. The expansile growth invaded zygomatic
bones bilaterally and multiple radiolucent lesions in the
anterior ends of all ribs were found [10]. Similar lesions in
ribs were radiographically detected in a 6-year-old patient
with cherubism [14]. The reported cystic lesions of the
ribs were asymptomatic in these cases and no follow-up
has been reported.
Cherubism with co-expressed craniosynostosis and
clubbed fingers has been described in a single family
[15,16], However, it is not clear whether the appearance of
these phenotypes is coincidental or associated with cher-
ubism. Extracranial involvement is extremely rare and
most cases have not been confirmed by genetic testing.
Ocular involvement
The characteristic upward gaze of patients with cherubism
provides the basis for the naming of the disease [1,2]. In
more severe forms of cherubism, the fibro-osseous tissue
extends into the inferior and/or lateral orbital walls. Physi-
cal displacement of the globe and retraction of the eyelids
r e s u l ti ne x p o s u r eo far i mo ft h es c l e r ab e n e a t ht h ei r i s .
The disease may also invade the retrobulbar spaces of the
orbits and cause displacement of the optic nerves and
proptosis [17]. The orbital effects of cherubism are due to
this displacement and not to direct invasion of the globe
and surrounding extraocular muscles. In one report, bilat-
eral orbital floor tumor masses developed after general
post-pubertal regression of the disorder [18]. At age
27 years the patient complained of reduced mobility of the
eyes. Displacement of the globes was caused by multilocu-
lar bony tumors filled with a jelly-like tissue. In another
case of a 27-year-old woman, the orbital lesions caused
optic nerve dysfunction with decreased contrast sensitivity
[19]. Ahmadi and colleagues describe a more severe case
of orbital involvement where the patient, at 31 years of
age, lost vision due to optic neuropathy, macular striae
and scarring caused by compression of the globe [20].
These reports indicate that continued ophthalmologic
supervision is mandatory even long after post-pubertal
regression of cherubism lesions in the maxillae.
Respiratory involvement
Respiratory problems are frequently absent but occasion-
ally manifest as upper airway obstruction caused by back-
ward displacement of the tongue [21] or obliteration of
the nasal airway. These findings may lead to mouth
breathing, snoring, chronic nasal infection and obstruc-
tive sleep apnea [22]. Nasopharyngoscopy, if possible,
and an overnight polysomnogram should be obtained if
concerns regarding a sleep disorder arise. Treatment
could include continuous positive airway pressure [21],
although this may not be possible because of the anat-
omy. Surgical intervention to alleviate nasal airway
obstruction and tongue displacement or tracheotomy
[22] may be necessary. There is one extreme case of cher-
ubism in the literature that describes an 8-year-old boy
with airway obstruction who died from consequent
pulmonary infections, aspiration and septicemia [23].
Dental impact
The impact of cherubism lesions on development and
eruption of the primary and permanent dentition varies
depending on the time of onset and severity of the
expansile lesions. The arrangement of primary teeth can
be disturbed [24,25]. Disruption of the secondary denti-
tion can include absent teeth (mostly molars), rudimen-
tary development of molars, abnormally shaped teeth,
partially resorbed roots or delayed and ectopically erupt-
ing teeth [24,26]. Tooth extraction may be needed, espe-
cially if teeth are “free-floating” in cherubism lesions [6]
or if they become ectopically impacted [27]. In more
severe instances, children may require prostheses that
need to be adjusted as the child grows or the swelling
within the oral cavity changes. A dental prosthesis may
improve the ability to chew and increase the self-esteem
of the child. Orthodontic treatment is appropriate after
growth is completed and when cherubism is regressing.
Inflammatory aspects
In the early stages of disease, patients may present with
lymph node enlargement. While most case reports of
children with cherubism describe lymphadenopathy, this
finding has not been monitored systematically and the
natural history is not known. Early reports suggest that
submandibular lymph nodes are enlarged during swelling
of the lower portions of the face while upper cervical
lymph nodes are involved when maxillary swelling occurs
[2,10]. In the past, cherubism has not been considered an
inflammatory bone disorder, but recent evidence in
mouse models points to the possibility that it is indeed
an autoinflammatory disease [28,29]. SH3BP2 is required
for functional B-cell receptor (BCR) signaling [30]. In
mouse models with mutant or ablated Sh3bp2 genes
[28,30,31] there is a delayed B-cell response [31]. The
ubiquitously expressed SH3BP2 protein has different
functions in different immune cells [30,32-35]. However,
in Sh3bp2
KI/KI mice, the cherubism mouse model, Ueki
et al. found that inflammatory lesions develop indepen-
dently of B- or T-cell involvement [28]. There are at least
two mechanisms that account for the cherubism-like
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caused by macrophages that produce high amounts of
TNF-a and 2) bone resorption caused by hyperactive
osteoclasts via activation of NFATc1 [28,36].
Biochemical markers
Mineral metabolism is normal in patients with cherubism,
and serum levels of calcium, parathyroid hormone (PTH),
parathyroid hormone related peptide (PTHrP), calcitonin
and alkaline phosphatase (ALP) are typically within nor-
mal range [37]. Urine markers of bone remodeling such as
pyridinium and deoxypyridinium cross-linking, hydroxy-
proline and calcium/creatinine have been reported to be at
the upper limits of normal in some children [37]. Serum
levels for alkaline phosphate may be increased during the
active stages of cherubism [24,38-40]. Serum phosphate
may also be increased [41]. Biochemical analysis can
differentiate cherubism from hyperparathyroidism, parti-
cularly in patients with brown tumors (epulis) of the jaw
or patients with the hyperparathyroidism-jaw tumor syn-
drome (HPT-JT) with mutations in the HRPT2 gene
encoding parafibromin [42-44]. Data about TNF-a levels
in serum of cherubism patients have not been published,
but there is preliminary evidence in a small group of
patients and age-matched controls that TNF-a is elevated
in cherubism patients (EJR personal communication).
Histology
Cherubism lesions resemble giant cell tumors because
they contain many giant-cells and mononuclear or stromal
cells (Figure 1). The fibrotic lesions are non-neoplastic.
Cherubism cannot be diagnosed by histology alone
because they are not distinguishable from other giant cell
lesions of bone [45]. Details of histological findings at the
various stages of cherubism are rarely described.
Chomette and colleagues describe 3 histologically,
immunohistochemically and ultrastructurally distinct
stages in cherubism lesions [46]. In the first, osteolytic
stage the authors found numerous round, fusiform and
multinucleated giant-cells. The giant osteoclast-like cells
are tartrate resistant acid phosphatase (TRAP) positive.
The tissue of the lesions is well vascularized. Fibroblastic
cells with fewer giant-cells can be found in the periphery
of the lesions. Hemosiderin, a breakdown product of
hemoglobin and a sign of hemorrhage, is observed in
endothelial cells and some surrounding fibroblasts.
The second stage is characterized by proliferative spindle
cells, which the authors associated with a reparative stage.
Fibroblastic nodules with central vessels dominate the
lesion while some osteogenesis can be observed near the
cortex of the bone. Newly formed bone matrix and osteoid
should be seen.
The third stage is attributed to bone formation with
cells staining positive for alkaline phosphatase
(presumably differentiating osteoblasts) and high levels
of ATPase (presumably associated with mineralizing
matrix). The tissue contains more collagen fibers and
fewer cells.
Ultrastructurally, the authors describe the multinu-
cleated giant cells as osteoclasts, the ovoid cells as meta-
bolically active young fibroblasts or osteoblasts, and the
elongated fibroblastoid cells as presumably fibroblasts or
myofibroblasts.
While these characteristic stages together may not be
seen in the same biopsy specimen, most histopathological
descriptions agree on the presence of spindle cells
embedded in interstitial collagen fibers and osteoclastic
giant-cells. Hemosiderin deposition is frequently found
[25,47]. Cytological examination after fine needle aspira-
tion can identify stromal cells and giant-cells, but its use-
fulness for diagnosis is questionable [48,49] unless coupled
with molecular analysis of SH3BP2.
Psychosocial considerations and quality of life
The obvious concern of patients and their families is the
facial disfigurement that is evident in cherubism. A second
consideration is the possibility of genetic transmission to
future children. Support groups (see below) and genetic
counseling (see below) may help with management of
these concerns. These supporting services function to aug-
ment the help available from family and friends. The
shared experiences of other cherubism patients can be
encouraging, e.g., the positive view on life of one severely
affected patient published on the web site of the British
Broadcasting Corporation (BBC): http://news.bbc.co.uk/2/
hi/uk_news/magazine/3128203.stm.
Diagnostic considerations and differential
diagnosis
The diagnosis of cherubism is based on patient age, family
history, clinical examination, radiographic findings, bio-
chemical analyses and molecular analysis.
The classic clinical appearance of the cherubic face
includes bilateral, symmetric, painless fullness of the
cheeks and mandible in children at 2 to 7 years of age,
when the diagnosis of cherubism is usually made. Retrac-
tion of the lower eyelids from bilateral mandibular and
maxillary enlargement results in exposure of the sclera
below the iris and an apparent upward gaze as described
by Jones in 1933. However, this classic appearance is not
infrequently absent and the patient may present with bilat-
eral multicystic lesions which enlarge the mandible. These
may be an incidental finding on radiographic examinations
performed for other reasons such as trauma or during
routine dental examinations.
Enlargement of the cervical lymph nodes that contri-
bute to the patient’s full-faced appearance, a V-shaped
palate with a high arch, early loss of primary teeth and
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are common findings in patients with cherubism. Orbi-
tal involvement may appear late in affected individuals.
This is manifest by osseous orbital expansion, globe dis-
placement, proptosis, diplopia, optic neuropathy and
loss of vision [18,20,50].
There have been reported cases of cherubism with
massive enlargement of the jaws and backward displace-
ment of the tongue resulting in airway obstruction and
obstructive sleep apnea, speech, mastication and swal-
lowing problems [21,22]. Some patients with severe
cherubism report episodic pain [17,22,23,51,52]. Patients
with aggressive, rapidly progressing cherubism should
be evaluated by a craniofacial team consisting of a sur-
geon (oral and maxillofacial surgeon, plastic surgeon,
otolaryngologist), geneticist/genetic counselor, ophthal-
mologist, dentist/orthodontist and child psychologist/
social worker and nurse.
At birth no signs of cherubism are present. Swelling of
the jaws usually appears between 2 and 4 years of age. A
rapid increase in size of the lesions and the affected jaws
follows until the age of 7-8 years. After that, lesions
remain unchanged or increase slowly until puberty
(Figure 2). Around the age of puberty, the condition
begins to regress and facial deformity starts to improve,
although lesions can be still seen on radiographs. By 30
years of age, lesions are frequently not detectable. In a
follow-up study of 18 patients with cherubism, von
Wowern found progressive new bone formation in the
lesions of patients over 20 years of age [27]. By 41 years
of age, the bone structure in the affected areas was com-
pletely normal. Diagnosis in adults with a mild form of
cherubism, not appreciated in childhood can be difficult
as lytic bone cysts fill in with bone and may not be
radiographically detectable. However, in rare instances
actively expanding lesions in suspected cherubism may
be diagnosed in adults [12].
Although not pathognomonic for cherubism, the radio-
graphic findings of bilateral, multilocular, radiolucent
areas within the mandible, usually located at the angles
and rami, should raise the suspicion for the disease. The
coronoid processes are commonly involved, whereas the
condyles are rarely affected. Lesions in the mandible are
usually symmetric, whereas those in the maxilla may be
asymmetric [4]. Imaging typically shows expansile remo-
deling of the involved bones, thinning of the cortices, and
multilocular radiolucencies with a coarse trabecular
pattern.
Biopsy and histopathologic examination are not
required in most cases to establish the diagnosis of cher-
ubism. However, when performed, numerous osteoclast-
like multinucleated giant cells in a moderately loose
fibrous stroma are present. Thus cherubism is considered
to be a fibro-osseous disorder. Ovoid to spindle shaped
Figure 1 Typical histopathology of Cherubism. A histological section from a cherubism lesion demonstrates the typical finding of multinucleated
osteoclast-like giant cells (arrows) near bone and within soft fibrous stroma.
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ous small vessels with large endothelial cells and perivas-
cular capillary cuffing are also present. Eosinophilic
cuffing appears to be specific to cherubism. However,
these deposits are not present in many cases, and their
absence does not exclude the diagnosis of cherubism
[53]. The histological findings of cherubism are similar to
those of aggressive or non-aggressive giant cell lesions,
myxoma, aneurysmal bone cyst and hemangioma and
other vascular lesions.
Gene testing is recommended to determine whether a
mutation in the cherubism gene SH3BP2 is present [54]
and to confirm the clinical diagnosis of cherubism. For
molecular analysis, genomic DNA from a blood sample or
tissue from lesions is used for sequence analysis. Cherub-
ism is an autosomal dominant disorder but most cases are
due to de novo mutations. Therefore, the absence of a
positive family history does not rule out the possibility of
cherubism.
An important component in the management of cherub-
ism is the differential diagnosis which includes brown
tumor of hyperparathyroidism, giant cell lesions, Noonan/
multiple giant cell lesion syndrome, fibrous dysplasia,
aneurysmal bone cyst and the hyperparathyroidism-jaw
tumor syndrome (HPT-JT). The limited and symmetrical
distribution of the cherubism lesions can often facilitate dis-
tinction of cherubism from these other conditions, and of
course mutation analysis of SH3BP2 can confirm the diag-
nosis. If no mutation in SH3BP2 is found cherubism cannot
be excluded because of possible genetic heterogeneity.
Hyperparathyroidism may be differentiated by analysis
of parathyroid hormone levels, calcium, phosphorous
and alkaline phosphatase. However, hyperparathyroidism
is rare in children except in the setting of chronic renal
Figure 2 A. Photograph of a 10 year old girl with bilateral cheek and jaw swelling. Cherubism was confirmed with genetic testing that was
positive for the SH3BP2 gene. The patient had genetic counseling and was followed longitudinally. B. Patient one year later with no progression
of facial swelling. C. CT scan at initial presentation showed typical bilateral lytic lesions in the mandible that remained unchanged at follow ups.
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sia [55] and Noonan/multiple giant cell lesion syndrome
[56-58] can be also be identified by genetic testing.
Noonan syndrome was first d e s c r i b e di n1 9 6 3a n di s
characterized by short stature, hypertelorism, prominent
posteriorly angulated ears, congenital heart defect, low
normal intelligence or developmental delay, cryptorchid-
ism in males, and bleeding disorders [59]. In 1986,
Chuong and colleagues published a series of 17 patients
with giant cell lesions of the jaws studying the correlation
of histologic appearance to biologic behavior [60]. Two
of these patients had Noonan syndrome and bilateral
giant cell lesions of the mandible and the maxilla. Dunlap
et al. first reported on the Noonan syndrome and cherub-
ism association and presented 4 children at age 4 to 8
years old with the combination of the two entities [61].
They considered the 2 patients with Noonan syndrome
reported by Chuong et al. having cherubism as well.
Later, in 1991, Cohen and Gorlin reviewed 15 cases with
Noonan syndrome and giant cell lesions and proposed
the name Noonan-like/multiple giant cell lesion syn-
drome and considered it to be separate from Noonan
syndrome and cherubism [62]. Following that, 5 more
cases of the Noonan-like/multiple giant cell lesion syn-
drome were published [63-65].
Later, mutations of the PTPN11 gene [56-58,66] and the
SOS1 gene [67] were identified in patients with Noonan
syndrome. These findings support the notion that the
giant cell lesions in patients with Noonan syndrome are
distinct from cherubism. Molecular analysis has led to the
consideration of the Noonan syndrome with multiple
giant cell lesions as a variant within the Noonan syndrome
spectrum [57,67] and the term Noonan-like/multiple giant
cell lesion syndrome should no longer be used. Rather
Noonan/multiple giant cell lesion syndrome is more
appropriate. There has also been a report of bilateral man-
dibular lesions in association with neurofibromatosis and a
mutation in the NF1 gene, which is associated with neuro-
fibromatosis and with Noonan Syndrome [68]. Differentia-
tion between cherubism and Noonan/multiple giant cell
lesion syndrome is important as giant cell lesions may
behave aggressively in the latter and can lead to consider-
able morbidity if not treated appropriately [69]. Giant cell
lesions in Noonan patients can easily be mistaken for
cherubism if the lesions appear symmetrically in maxilla
and mandible (Figures 3 & 4).
Cases of cherubism associated with other disorders
such as fragile X syndrome, gingival fibromatosis with
psychomotor retardation, neurofibromatosis type 1,
and craniosynostosis have been published in the litera-
ture [15,70-72]. Finally, cherubism has been reported
to be associated with Ramon syndrome [73] and Jaffe-
Campanacci syndrome ([61]. Ramon syndrome is
extremely rare with only 8 cases reported in the litera-
ture and presents with mental retardation, short sta-
ture, gingival fibromatosis and epilepsy [73,74].
Similarly rare is Jaffe-Campanacci syndrome [75],
which includes non-ossifying fibromas that can be
localized in long bones and/or jaw bones, mental retar-
dation, café au lait spots, hypogonadism, ocular and
cardiovascular anomalies (reviewed in [76]. However,
to our knowledge only eccentric or unilateral mandibu-
lar or maxillary lesions have been described in the lit-
erature for Jaffe-Campanacci syndrome [61,77].
Genetic origin, testing and counseling
The familial form of cherubism occurs typically in an
autosomal dominant trait with mutations in the SH3-
domain binding protein 2 (SH3BP2) [54] on chromosome
4p16.3 [78,79]. However, approximately 50% of all cases of
cherubism with mutations in SH3BP2 identified at the
University of Connecticut Health Center (UCHC) had no
family history and were assumed to be de novo mutations.
Germline mosaicism in parents is rare and while we can-
not exclude this possibility, germline mosaicism is highly
unlikely to account for these cases. In a few instances
patients have been clinically diagnosed with cherubism
but no mutation in SH3BP2 has been found, suggesting
the possibility of genetic heterogeneity. An autosomal
recessive mode of inheritance has been suggested in some
instances where signs of cherubism could not be found in
carriers of the older generation [11]. It is important to
note that the expressivity of cherubism is highly variable
and mild forms of cherubism may be undiagnosed. Diag-
nosis of cherubism in older patients where a mild pheno-
type has been missed may not be possible as cherubic
lesions in adults fill with normal mandibular bone and
m a yn ol o n g e rb ed e t e c t e db yr a d i o g r a p h s[ 2 7 ] .T h e s e
considerations put reports of reduced penetrance in
females into question [8,80].
Gene testing for known mutations in the SH3BP2
gene [9] is offered by several commercial reference
laboratories and testing on a research basis is available
(see GeneTests: http://www.ncbi.nlm.nih.gov/sites/Gen-
eTests/?db=GeneTests for updated information). Testing
for a cherubism mutation may help to confirm the
diagnosis.
Counseling by a medical geneticist or genetic counse-
lor is recommended if family members are concerned
that they may have cherubism. A gene test may resolve
the concern if a mutation has been identified in the pro-
band. Siblings of patients should be evaluated by physi-
cal examination, panoramic radiographs and genetic
testing. Updated information about prenatal testing and
preimplantation testing is available at GeneTests (http://
www.ncbi.nlm.nih.gov/sites/GeneTests/?db=GeneTests).
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Page 7 of 14Figure 3 Noonan/multiple giant cell lesion syndrome. A 20-year old woman with Noonan/multiple giant cell lesion syndrome with bilateral
involvement of the mandible and the maxilla. A and B. Frontal and submental photographs reveal prominent maxillary and mandibular
contours, slight frontal bossing and increased intercanthal distance, downslanting palpebral features, epicanthal folds and posteriorly angulated
ears. Lesions were painless to palpation. C and D. Coronal and 3D CT scan at initial presentation demonstrate involvement of the maxilla,
including the maxillary sinuses and the nasal-maxillary region and the mandible from the antegonial notch to antegonial notch. The lesions are
expansile and mixed radiolucent - radiopaque with cortical thinning and expansion into the orbits bilaterally. Patient was positive for a Noonan
syndrome mutation in SOS-1. She underwent a contour resection of the maxillary and the mandibular giant cell lesions in two sessions.
Postoperatively, she was treated with 4 courses of zoledronic acid, given at 6-week-intervals. E and F. Post-treatment frontal and submental
photographs.
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Mild forms of cherubism without facial dysmorphology,
dental and ocular involvement may not require treatment
as cherubism is expected to regress spontaneously after
puberty (Figure 2). Management in these cases consists
of longitudinal observation. During the growth phase of
the lesions, annual clinical and radiographic examination
with a panoramic or other appropriate radiograph is sug-
gested. Follow-up every 2 to 5 years is advisable after the
disease becomes quiescent. Expansion of fibrous lesions
in severe cases may regress well after adolescence
[6,11,27,53,81,82] . In other instances actively expanding
lesions in suspected cherubism may still be diagnosed in
adults [12].
Surgical intervention is indicated when aesthetic or
functional concerns arise including nasal obstruction,
proptosis or facial deformity. Options for surgical man-
agement include partial resection, contour resection,
curettage or a combination of these [83]. Surgical proce-
dures should be performed after puberty when the
lesions are quiescent. Severe aesthetic or functional pro-
blems may justify intervention prior to puberty. Orbital
surgery may be required in rare cases when tumor tissue
invades the floor of the orbits to a degree where it leads
to the displacement of globes or loss of vision is sus-
pected due to optic atrophy [19,50].
Development of dentition should always be closely mon-
itored. Roots may resorb or tooth displacement can occur
in cases where lytic lesions develop around erupting
secondary dentition or teeth may appear missing or to
float in the lesion [11]. The problem of early loss of decid-
uous teeth, absence, delayed development or eruption of
Figure 4 Imaging studies of the patient in Figure 3 pre-treatment (A, C, E) and post-treatment (B, D, F). A and B. Panoramic radiographs. C and
D. Lateral cephalograms. E and F. 3D CT scans. Pre- and post-treatment images show improvement of the giant cell lesions and the contours of
the mandible.
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Page 9 of 14the permanent teeth is difficult to treat and no satisfactory
solution is available. Space maintainers are used while
waiting for the permanent teeth to erupt. Malocclusion is
a major concern. Surgical exposure of impacted teeth is
sometimes necessary (Figure 5) [81].
Because the expressivity of cherubism is variable, even
within families, it is not surprising that reports of surgical
outcome are variable as well. In a few studies, surgical
contouring during the growth phase was associated with
rapid regrowth of the tumor [84,85]. In addition, Shah et
al. reported a case of leiomyosarcoma that arose in the
mandible of a 10-year-old child with cherubism after two
surgical recontouring procedures [39]. Favorable results
after curettage and recontouring performed during the
growth phase of cherubism have been reported as well.
Dukart et al. reported one case of cherubism in which
surgical intervention arrested active growth of remnant
lesions while stimulating bone regeneration [86]. Von
Wowern reported 18 patients with cherubism who
underwent biopsy with or without autotransplantation of
ectopically erupted teeth. Surgical treatment did not pro-
voke progression of the lesions in any of these cases [27],
which is consistent with other reports [40,41].
Raposo-Amaral and colleagues [7] reported on exten-
sive resection in 8 children age 6 to 15 years old with
severe cherubism. Surgical resection during the prolifer-
ating phase of the disorder was performed in 2 stages to
prevent excessive blood loss. The maxilla and orbits were
contour-resected first and the mandible 6 months later
through intraoral and extraoral incisions. Patients were
followed for 2 to 18 years and no recurrence was found
in any of the patients. Patients and authors were satisfied
with the outcome and the authors suggest that thorough
removal of affected tissue appears to arrest the prolifera-
tion of any remaining tumor tissue.
Radiation therapy has been described in the literature
for the management of cherubism. However, radiation
therapy is contra-indicated in this benign condition
because of the potential for long-term adverse conse-
quences such as retardation of jaw growth, osteoradione-
crosis and increased incidence of induced malignancy
[53,84].
Calcitonin has been used for the treatment of central
giant cell granuloma (CGCG) with successful outcome
[87] and experimental use of calcitonin for the treatment
of cherubism has been suggested [37]. In an 11-year-old
boy with bimaxillary cherubism, lesions regressed and
normal mandibular contour was restored with adminis-
tration of salmon calcitonin nasal spray daily for
15 months [88].
However, Lannon and Earley treated a 7-year-old boy
with significant mandibular enlargement and facial
deformity due to presumed cherubism with calcitonin
for 6 month without any visible effect [53]. The effect of
calcitonin in giant cell granulomas can be seen after
prolonged treatment (up to 18 months) and thus, calci-
tonin treatment would not be preferred for rapidly
growing lesions [89,90]. Further studies to document the
efficacy of calcitonin in the treatment of cherubism are
required before it can be recommended as a conven-
tional therapy.
Kaban et al. reported the first use of interferon for
management of aggressive giant cell lesions in 1999 [91].
This group has also used a combination of contour resec-
tion and adjuvant interferon therapy for management of
giant cell lesions in Noonan-multiple giant cell lesion
syndrome. It is possible interferon could work in the pro-
liferating phase of cherubism when vascular proliferation
and multiple giant cells are present. Further investigation
is warranted.
Prognosis
Most cases of cherubism regress spontaneously after pub-
erty. Carvalho Silva and colleagues describe that the cher-
ubism lesions in 7 of 8 of their patients stabilized by age
12 years and regressed thereafter [92]. One more severely
affected patient showed features of cherubism at age 20.
Radiographic examination at follow-up visits revealed fill-
ing of the radiolucent lesions with bone as early as 2 years
after stabilization and in most patients when they were in
their twenties. In some cases the radiolucencies were
replaced with sclerotic bone later in life. In more severe
cases radiolucencies can remain. Corrective surgery may
be performed after cherubism lesions become quiescent to
achieve facial features that are acceptable to the patient. It
is interesting to note that spontaneous fracture of jaw
bones, even in severely affected patients, is not reported
[7].
Future perspectives (treatment modalities based
on current research)
Ongoing research strongly suggests that abnormal
inflammatory responses are an important component of
the pathophysiology of cherubism. Research in a mouse
model suggests that high levels of tumor necrosis factor-
a (TNF- a) in the circulating blood system contribute to
the progression of cherubism [9,28] A therapy to reduce
TNF- a levels could be possible if this hypothesis holds
true in humans as well. Such TNF- a blocker or antibody
therapies have been approved for a number of other
immune-mediated inflammatory diseases (reviewed in
[93,94]). Although the mechanisms by which TNF- a
antagonists work are not fully understood, it is conceiva-
ble, that reducing pro-inflammatory cytokine production
and a reduction in osteoclast formation and resorption
could have a positive effect on the rate of bone resorption
and cherubism tissue expansion. However, experimental
treatment with TNF- a blocking therapy in combination
Papadaki et al. Orphanet Journal of Rare Diseases 2012, 7(Suppl 1):S6
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Page 10 of 14Figure 5 Cherubism. A 5 year old boy who after a mild trauma underwent a dental evaluation. A. Examination revealed marked fullness of the
cheeks, expansion of the malar eminences and the mandibular angle regions. B. Intraoral examination was significant for expansion of the
mandibular alveolus in the permanent molar regions. C and D. Panoramic radiograph revealed bilateral radiolucent lesions in the mandible and
maxilla (arrows). The lesions were displacing the permanent second molar tooth buds superior to the first molar teeth. E and F. Intraoral biopsy
and removal of the displaced second molar tooth buds leaving the first molar tooth buds in place to erupt. Pathologic diagnosis was fibro-
osseous lesion consistent with cherubism.
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Page 11 of 14with bisphosphonates in a single patient showed no
improvement [95]. The rate of progression during treat-
ment and 6 month after treatment was considered the
same.
More potential therapeutic targets will arise as mole-
cular mechanisms for the action of mutant SH3BP2
become known. For example, the central role of the
nuclear factor of activated T cells c1 (NFATc1) in regu-
lating osteoclast gene express i o nm a k e st h i st r a n s c r i p -
tion factor another possible target for interfering with
excessive bone resorption [96].
Ueki and coworkers hypothesize that – at least in
mice – a hyper-active host response to oral pathogens
or to physical damage may trigger the onset of cherub-
ism [97]. Physical damage due to rapid bone remodeling
for erupting secondary teeth could incite the bone
resorptive lesions in cherubism. If this hypothesis holds
true, new molecular targets for preventing cherubism in
patients who have been diagnosed with a SH3BP2 gene
mutation may be efficacious.
Support groups
Several support and advocacy groups offer information
and support for individuals affected with craniofacial dis-
orders (Table 2). Updated information about cherubism
may also be obtained from websites such as GeneTests.
Conclusions
Although rare, cherubism has a significant impact on
affected children and their families. This is especially true
in those cases where aggressive growth leads to facial
d e f o r m i t ya n df u n c t i o n a lp r o b l e m s .I nt h em a j o r i t yo f
cases, cherubism is self-limiting and no surgical treatment
is necessary apart from longitudinal clinical and radio-
graphic observation, which should continue into adult-
hood. In cases of rapidly proliferating cherubism with
significant functional consequences, resection may be indi-
cated. Operative intervention does not change the disease
progression but may improve function and appearance.
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